These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 14720132)

  • 1. Cost-effectiveness versus cost-utility analysis of interventions for cancer: does adjusting for health-related quality of life really matter?
    Tengs TO
    Value Health; 2004; 7(1):70-8. PubMed ID: 14720132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. When does quality-adjusting life-years matter in cost-effectiveness analysis?
    Chapman RH; Berger M; Weinstein MC; Weeks JC; Goldie S; Neumann PJ
    Health Econ; 2004 May; 13(5):429-36. PubMed ID: 15127423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Which is more valuable, longer survival or better quality of life? Israeli oncologists' and family physicians' attitudes toward the relative value of new cancer and congestive heart failure interventions.
    Greenberg D; Hammerman A; Vinker S; Shani A; Yermiahu Y; Neumann PJ
    Value Health; 2013; 16(5):842-7. PubMed ID: 23947979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Economic evaluation of targeted cancer therapy].
    Ikeda S
    Gan To Kagaku Ryoho; 2013 Aug; 40(8):967-70. PubMed ID: 23986036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-utility analysis of cataract surgery in the second eye.
    Busbee BG; Brown MM; Brown GC; Sharma S
    Ophthalmology; 2003 Dec; 110(12):2310-7. PubMed ID: 14644712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Global cost-effectiveness of cataract surgery.
    Lansingh VC; Carter MJ; Martens M
    Ophthalmology; 2007 Sep; 114(9):1670-8. PubMed ID: 17383730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness and cost-effectiveness of the implantable miniature telescope.
    Brown GC; Brown MM; Lieske HB; Lieske PA; Brown KS; Lane SS
    Ophthalmology; 2011 Sep; 118(9):1834-43. PubMed ID: 21723614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?
    Braithwaite RS; Meltzer DO; King JT; Leslie D; Roberts MS
    Med Care; 2008 Apr; 46(4):349-56. PubMed ID: 18362813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjusting to changes in health: implications for cost-effectiveness analysis.
    Sharma R; Stano M; Haas M
    J Health Econ; 2004 Mar; 23(2):335-51. PubMed ID: 15019760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The value-based medicine comparative effectiveness and cost-effectiveness of penetrating keratoplasty for keratoconus.
    Roe RH; Lass JH; Brown GC; Brown MM
    Cornea; 2008 Oct; 27(9):1001-7. PubMed ID: 18812762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
    Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
    Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration.
    Brown MM; Brown GC; Brown HC; Peet J
    Ophthalmology; 2008 Jun; 115(6):1039-1045.e5. PubMed ID: 17976724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does adjusting for health-related quality of life matter in economic evaluations of cancer-related interventions?
    Greenberg D; Neumann PJ
    Expert Rev Pharmacoecon Outcomes Res; 2011 Feb; 11(1):113-9. PubMed ID: 21351863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative outcomes and cost-utility following surgical treatment of focal lumbar spinal stenosis compared with osteoarthritis of the hip or knee: part 2--estimated lifetime incremental cost-utility ratios.
    Rampersaud YR; Tso P; Walker KR; Lewis SJ; Davey JR; Mahomed NN; Coyte PC
    Spine J; 2014 Feb; 14(2):244-54. PubMed ID: 24239803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cost--utility analysis of treatment options for inguinal hernia in 1,513,008 adult patients.
    Stylopoulos N; Gazelle GS; Rattner DW
    Surg Endosc; 2003 Feb; 17(2):180-9. PubMed ID: 12415334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metastatic colorectal carcinoma: cost-effectiveness of percutaneous radiofrequency ablation versus that of hepatic resection.
    Gazelle GS; McMahon PM; Beinfeld MT; Halpern EF; Weinstein MC
    Radiology; 2004 Dec; 233(3):729-39. PubMed ID: 15564408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting.
    Manser R; Dalton A; Carter R; Byrnes G; Elwood M; Campbell DA
    Lung Cancer; 2005 May; 48(2):171-85. PubMed ID: 15829317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study.
    Badri M; Cleary S; Maartens G; Pitt J; Bekker LG; Orrell C; Wood R
    Antivir Ther; 2006; 11(1):63-72. PubMed ID: 16518961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of multilevel hemilaminectomy for lumbar stenosis-associated radiculopathy.
    Parker SL; Fulchiero EC; Davis BJ; Adogwa O; Aaronson OS; Cheng JS; Devin CJ; McGirt MJ
    Spine J; 2011 Aug; 11(8):705-11. PubMed ID: 21641874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.